| Primary information |
|---|
| sequence ID | Seq_7271 |
| Peptide sequence | SLAELGGHLDQQVEEF |
| CancerPDF_ID | CancerPDF_ID80, CancerPDF_ID352, CancerPDF_ID1078, CancerPDF_ID1391, CancerPDF_ID2607, CancerPDF_ID9561, CancerPDF_ID12680, |
| PMID | 16896061,19795908,16395409,21136997,21136997,21533267,25168216 |
| Protein Name | Apolipoprotein A-IV,Apolipoprotein A-IV,Apolipoprotein A-IV,Apolipoprotein A-IV,Apolipoprotein A-IV,Apolipoprotein A-IV,Apolipoprotein A-IV |
| UniprotKB Entry Name | APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN |
| Fluid | Serum,Plasma,Serum,Serum,Plasma,Serum,Serum |
| M/Z | 1771.81,886.43,1771.81,1770.84244,1770.8424,886.42,NA |
| Charge | 1,2,1,1,1,2,NA |
| Mass (in Da) | 1771.84,NA,NA,NA,NA,NA,NA |
| fdr | NA,NA,NA,NA,NA,NA,1771.8 |
| Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,LC-MS,LC-MS |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,LC/MS/MS,LC-MS/MS |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,LC-ESI-MS,Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Label Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,less than 7%,less than 1 “5,0.001,NA,1.49,NA |
| CancerPDF_ID | CancerPDF_ID80, CancerPDF_ID352, CancerPDF_ID1078, CancerPDF_ID1391, CancerPDF_ID2607, CancerPDF_ID9561, CancerPDF_ID12680, |
| p-Value | 1.00E-05,NA,3.05E-06,2.82E-04,NA,NA,4.80E_05 |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT |
| Length | 16,16,16,16,16,16,16 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Normal,Lung adenocarcinoma,Renal cell carcinaoma |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,Swissprot Database (57.4),SwissProt Database |
| Modification | NA,NA,NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"40 normal, 28 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])",30 patients and 30 healthy controls,27 healthy individuals,62 lung adenocarcinoma and 30 healthy control,"30 RCC patients and 30 healthy controls for training dataset and 6 RCC patients, 6 control in independent validation dataset" |
| Regulation | NA,NA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =148, 220 and 1 in prostate, bladder and breast cancer respectively",Differentially expressed between cancer vs normal,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal",Upregulated in cancer v/s Normal |
| Validation | Independent validation,NA,Independent validation,Leave One out Cross validation,Leave One out Cross validation,MRM-based validation of 19 candidates,Independent validation |
| Sensitivity | 95% on independent dataset,NA,97.5% on independent validation dataset,0.898,NA,NA,100 % (for 19 peptide signatures) |
| Specificity | 95% on independent dataset,NA,NA,0.946,NA,NA,NA |
| Accuracy | NA,NA,97.5 % on validation dataset,0.917,NA,NA,AUC : 0.850 |
| Peptide Atlas | PeptideAtlas |
| IEDB | |